Barcelona

Scientific Programme

The Academy day will have a range of educational symposia covering many different topics and will include interactive sessions. The main scientific programme will include new topics and new ISBT speakers. 

The scientific programme will be plublished on this page soon. 
 

Programme per day

09.00-11.00 Topic / Speaker
09.00-09.15 Introducción
J. Cárdenas & E. Muñiz-Diaz
09.15-09.45 Un enfoque práctico y realista de la implementación de las  “Directrices de buenas prácticas” en los centros de transfusión
J. Arroyo 
09.45-10.15 Estado actual del cribado del virus de la hepatitis E
S. Sauleda 
10.15 - 10.30 Discusión 
10.30-11.00 Coffee break
11.00-13.30 Topic / Speakers
11.00-11.30 Contaminación bacteriana de los concentrados de plaquetas: ¿un reto pendiente?
M. Lozano
11.30-12.00 Interferencias en las pruebas de compatibilidad generadas por los nuevos tratamientos con anticuerpos monoclonales.
Posibles soluciones
E. Muñiz-Diaz
12.00-12.30 Anemia, transfusión y mortalidad en el enfermo cardiaco
P. Cepas
12.30-13.00 Obtención y producción de CAR-T
D. Benitez
13.00-13.30 Discusión
13.30 Lunch break
14.30-16.30 Topic / Speaker
14.30-15.00 Papel, objetivos y recursos de la I+D+i en Centros de Transfusión
J. García
15.00-15.30 Aspectos éticos relacionados con la donación de sangre
H. Gonçalves / M. Jose Gomes
15.30-16.00 Grupo Cooperativo Iberoamericano de Medicina Transfusional (GCIAMT)
S. Kuperman
16.00-16.25 Discusión
16.25-16.30 Conclusiones
J. Cárdenas & E. Muñiz-Diaz
08.30-10.00 Aspects to be considered to connect with the donor community
08.30-09.00 What motivates or hinders donors to give blood?
E. Merz (Netherlands)
09.00-09.30 Profile of non-donors, occasional donors and regular donors
T. Daruma (Malaysia)
09.30-10.00 Bringing back lapsed donors
J. Leon (Australia)
08.30-10.00 Transfusion prtocols in trauma and massive bleeding
08.30-09.00 Pathophysiology of trauma
TBA
09.00-09.30 Evidence for blood product use in trauma and massive bleeding
TBA
09.30-10.00 Mass casualty and emergency preparedness
H. Doughty (United Kingdom)
10.30-11.00 Coffee break
10.30-12.00 Advancing blood systems globally
10.30-11.00 The WHO vision for advancing blood systems
J. Epstein (USA)
11.00-11.20 Between ideals and reality
S. Owusu-Ofori (Ghana)
11.20-11.40 Strategizing WHO priorities and actions
D. Teo (Singapore)
11.40-12.00 Discussion
10.30-12.00 Solutions to unmet transfusion needs
10.30-11.00 Platelet refractoriness: options for the best match
P. Hoglund (Norway)
11.00-11.30 Ins-and outs of cold-stored platelets and their clinical use
T. Apelseth (Sweden)
11.30-12.00 Antigen-modified cultured red blood cells: how to produce and to use
M. Meinders (United Kingdom)
12.30-13.30 Lunch and Satellite Symposia
13.30-15.00 How to conduct research studies
13.30-14.00 Pitfalls in design and analysis in clinical studies
L. van de Watering (The Netherlands)
14.00-14.30 Blood loss around delivery: how to measure and to improve the care in a center in Ethiopia?
A. Tura (Ethiopia)
14.30-15.00 TBA
13.30-15.00 New laboratory techniques used in the transfusion laboratory to improve clinical advice and product selection
13.30-14.00 Next-generation-sequencing-based HLA typing: how is it done and what did it bring?
M. José Herrero (Spain)
14.00-14.30 An overview on digital-droplet PCR for precise fetal typing and the use of NGS-based red blood cell typing
H. O'Brien (Australia)
14.30-15.00 The collaboration between laboratory and the clinic to provide typed red blood cells in autoimmune haemolytic anaemia
M. Raos (Croatia)
15.00-15.30 Coffee break
15.30-17.00 All about the ISBT activities
15.30-15.50 Update on ISBT's educational activities
E.Herczenik (The Netherlands)
15.50-16.10 Why ISBT? What's in it for a YP?
T. Hutchinson (USA)
16.10-16.30 What and how to achieve to make molecular database accessible
TBA
16.30-16.50 Clinical Transfusion WP outreach activities
TBA
15.30-17.00 SCD and molecular techniques in treatment and transfusion policy
15.30-16.00 The clinical epidemiology of SCD in Africa
S. Uyoga (Kenya)
16.00-16.30 Current understanding of the molecular pathophysiology of SCD
H. Al Balushi (Oman)
16.30-17.00 Gene therapy for hemoglobinopathies: progress and future challengesc
W. El Nemer (France)
08.30-10.00 Donors and Donation
08.30-09.00 An update on the International Rare Donor Panel (IRDP); whats in the future? 
N. Thornton (United Kingdom)
09.00-10.00 Selected abstracts
08.30-10.00 Immunobiology 
08.30-09.00 Climate change and its affects on the Migration of Arboviruses: Impact on Blood Safety
J. Semenza (Sweden)
09.00-10.00 Selected abstracts
08.30-10.00 Clinical
08.30-09.00 Outcomes for clinical trials in transfusion: Is the bleeding score necessary?
Terry Gernsheimer (USA)
09.00-10.00 Selected abstracts
08.30-10.00 Cellular Therapies
08.30-10.00 Selected abstracts
08.30-10.00 Working Party session: Update of TTID Working Party Activities
08.30-08.45 Overview of Working Party
B. Custer (USA)
08.45-09.10 SRAP Subgroup
W. Steele (USA)
09.10-09.35 Parasites Subgroup
E. Bloch (USA)
09.35-10.00 Bacteria Subgroup
S. Ramirez (Canada)
08.30-10.00 Working Party session: Computer System Guideline Challenges
08.30-09.00 Computer System Infrastructure Qualifications – Expanding an Existing Validation Guideline
J. Andriessen (The Netherlands)
09.00-09.30 Complexities and Ramifications of a Traceability Guideline
M. Breard (USA)
09.30-10.00 Discussion
10.00-10.30 Coffee break

 

 

10.30-12.00 Plenary Session I: Post-partum hemorrhage: How can it be reduced?
10.30-11.00 Management of post-partum hemorrhage
R. Collis (United Kingdom)
11.00-11.30 Post partum hemorrhage in Africa
R. Larsen-Reindorf (Ghana) 
11.30-12.00 A multimedia approach to post partum haemorrhage
B. Hunt / M. Keep (United Kingdom)
12.00-14.00 Lunch break and Satellite Symposia
14.00-15.30 Donors and Donation
14.00-14.30 Iron monitoring in whole blood donors: seeking an optimal balance between donor availability and health
K. van den Hurk (The Netherlands)
14.30-15.30 Selected abstracts
14.00-15.30 Blood Products
14.00-14.30 Making whole blood for trauma available again
P. Young (USA)
14.30-15.00 Blood products exert inflammatory insults; are their consequences? 
F. Noizat-Pirenne (France)
15.00-15.30 Selected abstracts
14.00-15.30 TTID Abstract session
14.00-15.30 Management and Organisation
14.00-14.30 Patient Blood Management: Recommendations From the 2018 Frankfurt Consensus Conference
M. Mueller (Germany)
14.30-15.30 Selected abstracts
14.00-15.30 Young Investigators Session
14.00-15.30 Interactive workshop
14.00-15.30 Working Party Session: Quality Management
15.30-16.00  Break, exhibition and poster display

 

16.00-17.30 Clinical (Joint ISBT / AABB)
16.00-16.30 Epidemiology and National Trends in Pediatric Transfusion: Where do we stand?
R. Goel (USA)
16.30-17.00 Transfusion and Anemia Expert Initiative - Control/Avoidance of Bleeding (TAXI-CAB) 
M. Nellis (Israel)
17.00-17.30 Anemia at Pediatric Intensive Care Unit Discharge
P. Demaret (France)
16.00-17.30 Blood products: A Focus on Platelets
16.00-16.30 Alternative methods of platelet storage and pathogen reduction
T. Jimenez-Marco (Spain)
16.30-17.00 Platelets refrigerated and cryopreserved. A current alternative, valid and useful
J. Rivera (Spain)
17.00-17.30 Selected abstracts
16.00-17.30 Immunobiology 
16.00-16.30 Complement in transfusion medicine
M. Scully (United Kingdom)
16.30-17.30 Selected abstracts
16.00-17.30 Immunology
16.00-16.30 Blood group antigens in the genomicera
C. Hyland (Australia)
16.30-17.30 Selected abstracts
16.00-17.30 Management and Organisation
16.00-16.30 Full electronic traceability: From collection to transfusion
M. Angel Vesga Carasa (Spain)
16.30-17.30 Selected abstracts
16.00-17.30 Update on Rh Disease and the WIRhE Initiative
16.00-16.20 The global epidemiology of Rh disease and the rationale for the WIRhE initiative
B. Stotler (USA)
16.20-16.40 Current issues in Rh disease: The perspective from Nigeria
A. Okolo (Nigeria)
16.40-17.00 Improving Rh disease prevention in rural Pakistan: A scientific study
L. Pell (Canada)
17.00-17.20 Rh disease prevention: The European perspective
C. Toly Ndour (France)
17.20-17.30 Discussion
16.00-17.30 WP session IIII: Donors and Donation
16.00-16.30 Periodontitis in blood donors
C. Damgaard (Denmark)
16.30-17.00 Ethics in relation to plasma donors
F. Rossi (France)
17.00-17.30 The WHO viewpoint on donor ethics
Y. Abdella (Egypt)
20.00-23.00 Speakers Dinner
08.30-10.00 Donors and Donation
08.30-09.00 Lymphopenia in frequent Blood donors
M. Rahmani (Canada)
09.00-10.00 Selected abstracts
08.30-10.00 Blood products
08.30-09.00 In vitro RBC production for diagnostic purposes
N. Nogués (Spain)
09.00-10.00 Selected abstracts
08.30-10.00 Blood safety
08.30-09.00 Bacterial sepsis in transfusion recipients despite secondary mitigation strategies
M. Prax (Germany)
09.00-10.00 Selected abstracts
08.30-10.00 Immunology
08.30-09.00 New insights into Fetal/Neonatal Alloimmune Thrombocytopenia
N. Cooper (Germany)
09.00-10.00 Selected abstracts
08.30-10.00 Clinical
08.30-09.00 Management of massive haemorrhage
A.M. Gómez-Caro (Spain)
09.00-10.00 Selected abstracts
08.30-10.00 Working Party Global blood safety 
08.30-09.00 Production of virus-inactivated S/D-cryo in Egypt - Practical experience and impact on patient's health
M. El-Ekiaby (Egypt)
09.00-09.30 Thailand experience all the way from cryo, dry-heated cryo, and domestic industrial Factor VIII concentrate production
U. Charoonruangrit (Thailand)
09.30-10.00 A global perspective on availability of safe plasma products for treatment of bleeding disorders: filling the supply and safety gaps
Y. Maryuningsih (Indonesia)
10.00-10.30  Break, exhibition and poster display

 

10.30-12.00 Plenary Session II: The Gut Microbiome in transfusion medicine
10.30-11.00 Converting RBC units to group O with gut-derived bacteria
S. Withers (Canada)
11.00-11.30 How transfusion alters the gut microbiome and its implications
H.A. Goubran Messiha (Canada)
11.30-12.00 The microbiome of healthy blood donors and its role in potential transfusion reactions
B. Lelouvier (France)
12.00-14.00 Lunch break and Satellite Symposia
13.00-13.45 ISBT General Assembly
14.00-15.30 Blood products
14.00-14.30 IVIg: Are replacements available?
A. Lazarus (Canada)
14.30-15.30 Selected abstracts
14.00-15.30 Blood safety
14.00-14.30 Blood groups and the risk of thrombosis
D. Kenny (Ireland)
14.30-15.30 Selected abstracts
14.00-15.30 Immunology
14.00-14.30 Microparticles in transfusion medicine
E. Boilard (Canada)
14.30-15.30 Selected abstracts
14.00-15.30 Working Party Session: Rare Donors
14.00-14.30 Clinical Dilemmas in the Allocation of Rare Blood
V. Yahalom (Israel)
14.30-15.00 Ethical Dilemmas in the Allocation of Rare Blood
P. Flanagan (New Zealand)
15.00-15.30 Provision of Rare Blood: experiences from the Frontlines 
N. Thornton (United Kingdom)
14.00-15.30 Working Party Session: Haemovigilance 
14.00-14.10 Haemovigilance at the crossroads
J. Wiersum (The Netherlands)
14.10-14.30 Lessons learned from promoting data harmonisation and how we detect signals across plasma-derived medicines
E. Van Puijenbroek (The Netherlands)
14.30-14.50 Big Data and linking routine databases
S. Vossoughi (USA)
14.50-15.10 Update on collaborative HV activities in Spanish-speaking regions
E. Muñiz-Diaz (Spain)
15.10-15.30 Discussion
K. Land, moderator (USA)
14.00-15.30 Transfusion Practitioner session
14.00-14.30 Novice to expert trajectory – skills, attributes, behaviours and aptitude, competency framework
A. Miller (United Kingdom)
14.30-15.00 What technology will help or create challenges for the TP
M. Rowley (United Kingdom)
15.00-15.30 Extending the TP role and publications through research
E. Wood (Australia)
15.30-16.00 Coffee break, exhibition and poster display
16.00-17.30 Donors and Donation
16.00-16.30 Improving blood delivery to disaster-hit areas
X. Song (United Kingdom)
16.30-17.30 Selected abstracts
16.00-17.30 Clinical
16.00-16.30 The Bone Marrow microenvironment in SCD
L. Silberstein (USA)
16.30-17.00 Hemolysis in SCD and its Complications
K. Yazdanbakhsh (USA)
17.00-17.30 Selected abstracts
16.00-17.30 Cellular Therapy
16.00-16.30 Proven and Unproven cell therapies: What have we learned so far?  
F. Lim (Singapore)
16.30-17.00 Eye drops of human origin (EDHO): patients, donors and new products
C. Gabriel (Austria)
17.00-17.30 Selected abstracts
16.00-17.30 All you want to learn about Guidelines
16.00-16.30 How to develop international transfusion guidelines 
N. Shehata (Canada)
16.30-17.00 Guideline implementation: successes and challenges – UK experience 
S. Allard (United Kingdom)
17.00-17.30 Adapting guidelines for global application – how can ISBT help
R. Rama Sharma (India)
16.00-17.30 Working Party Session: Red cell terminology 
16.00-16.20 What is a “blood group”, and what is an “antigen” – general definitions 
G. Daniels (United Kingdom)
16.20-16.40 The new blood group system No. 37 – “KANNO” 
K. Ogasawara (Japan)
16.40-17.00 The new blood group system No. 38 - “SID”
M. Olsson (Sweden)
17.00-17.20 The (presumably) new blood group system No. 39 – “CTL2”
T. Peyrard (France)
17.20-17.30 Discussion
16.00-17.30 Working Party Session: Blood supply management
16.00-16.30 Results of Survey on Best Practice for "Reducing out-dating of platelets and Red cell'
E. Jansen (The Netherlands)
16.30-17.00 Approach to reducing/minimizing expiry of blood and components in Australia
G. Wilkie (Australia)
17.00-17.30 TBA
17.45-18.45 Poster Session
19.00-23.00 Congress party
08.30-10.00 Jean Julliard Prize session
10.30-12.00 Presidential Award Session
12.00-13.30 Lunch and satellite symposia

 

 

13.30-15.00 Donors and Donation
13.30-14.00 Strategies and theories to attract and retain blood donors: Is it just a warm glow
E. Ferguson (United Kingdom)
14.00-15.00 Selected abstracts
13.30-15.00 Blood products
11.30-12.00 Use of whole blood as the routine transfusion product in Africa
K. Maitland (United Kingdom)
13.30-15.00 Immunology
13.30-15.00 Selected abstracts
13.30-15.00 Blood safety
13:30-14:00 Genomics and big data in blood safety
H. Ullum (Denmark)
13.30-15.00 Working Party Session: Platelet immunobiology
  CD36, an important alloantigen on platelets and leukocytes 
M. Ando (Japan)
  Platelet and leukocytes in TRALI - players or bystanders?
J. Semple (Sweden)
  Diagnosing autoimmune responses to platelets and leukocytes: state of the art
U. Sachs (Germany)
15.00-15.30 Break, exhibition and poster display
15.30-17.00 Plenary Session III: Arthropod transmitted infections: New Strategies for eradication
15.30-16.00 The Monkeybar Project: identifying environmental factors for emerging zoonotic malaria 
K. Fornace (United Kingdom)
16.00-16.30 Engineering malaria resistance in mosquitoes: Gene Driving
A. Crisanti (United Kingdom)
16.30-17.00 Eliminating Arboviruses by modifying the insects gut microbiome
TBA
17.00-17.15 Closing ceremony